Depression of toxic effects of anticancer agents by selenium or pretreatment with metallothionein inducers.
D000818:Animals; D001729:Bismuth / Q000494:pharmacology*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D004317:Doxorubicin / Q000009:adverse effects*; D006321:Heart / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D008668:Metallothionein / Q000096:biosynthesis*; D051379:Mice; D012643:Selenium / Q000008:administration & dosage / Q000494:pharmacology*
D004317:Doxorubicin; D008668:Metallothionein; C010804:bismuth subnitrate; D012643:Selenium; D002945:Cisplatin; D001729:Bismuth